We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00510471
Recruitment Status : Terminated
First Posted : August 2, 2007
Last Update Posted : March 18, 2008
Sponsor:
Information provided by:

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : No date given
  Study Completion Date : No date given